GC녹십자셀은 개발 중인 키메릭 항원 수용체(CAR)-T 치료제의 동물실험 결과, 암세포의 100% 사멸 사례가 나왔다고 13일 밝혔다.
Green Cross Cell announced on the 13th that 100% of cancer cells were killed as a result of animal testing of chimeric antigen receptor (CAR)-T treatment under research.